Ellen Feigal, MD, Former Senior Executive with CIRM and the National Cancer Institute (NCI), Joins NDA Partners as Premier Expert

Share Article

NDA Partners announced today that Ellen G. Feigal, MD, an internationally recognized expert in therapeutic product development, hematology-oncology, cell therapies, and regulatory science, has joined the firm as a Premier Expert consultant. Dr. Feigal previously served as the Senior Vice President of Research and Development at the California Institute for Regenerative Medicine, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute (NCI).

News Image
Dr. Feigal is at the forefront of medical research and drug development in a broad spectrum of diseases, and brings industry-leading expertise for products under development to treat cancer, hematologic and neurologic disorders.

Dr. Carl Peck, MD, Chairman of NDA Partners LLC announced today that Ellen G. Feigal, MD, has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants whose expertise and professional stature enable them to bring extraordinary value to the company’s clients. Premier Experts collaborate to design and implement critical solutions to help clients successfully develop their medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.

Dr. Feigal was formerly Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; Executive Medical Director, Global Development, at Amgen; and Chief Medical Officer at Insys Therapeutics. She was a founding Director of the American Course on Drug Development and Regulatory Sciences. The course was developed under her leadership as a collaborative effort with the FDA, UC San Francisco’s Department of Bioengineering and Therapeutic Sciences, its Center for Drug Development Sciences, and the European Center of Pharmaceutical Medicine at the University of Basel. She has worked in clinical research and product development in positions at the Federal Government and non-profit institutes including Director of Medical Devices and Imaging at the Critical Path Institute, and Vice President of Clinical Sciences and Deputy Scientific Director at the Translational Genomics Research Institute. Dr. Feigal directed the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis after serving as Deputy Director, and was a senior investigator in the Cancer Therapy Evaluation Program.

“Dr. Feigal is at the forefront of medical research and drug development in a broad spectrum of diseases, and brings industry-leading expertise for products under development to treat cancer, hematologic and neurologic disorders,” said Dr. Peck. “These are areas where many promising new therapies are entering the drug development pipelines of our clients, and Dr. Feigal will be a welcome and invaluable contributor to their success.”

Dr. Feigal earned an MD at UC Davis, completed an internal medicine residency at Stanford, and a hematology/oncology fellowship at UC San Francisco. She was on the faculty at UC San Francisco, and UC San Diego, before joining the NCI.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include two former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 40 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Earle Martin
NDA Partners, LLC
540-923-4582
Email >